| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41584-018-0091-8 |
| P698 | PubMed publication ID | 30266977 |
| P50 | author | Ellen M Gravallese | Q117258216 |
| P2093 | author name string | Georg Schett | |
| P2860 | cites work | Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study | Q90575851 |
| Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 | Q24290619 | ||
| IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats | Q24294661 | ||
| IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis | Q24563235 | ||
| Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling | Q24625230 | ||
| Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants | Q24646663 | ||
| Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate | Q24658507 | ||
| The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity | Q26750673 | ||
| The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing | Q27687800 | ||
| Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice | Q28081074 | ||
| Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis | Q28246778 | ||
| Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 | ||
| Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1 | Q28585931 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Genetic and epigenetic fine mapping of causal autoimmune disease variants | Q28649603 | ||
| Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain | Q29614225 | ||
| Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla | Q30760660 | ||
| Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis | Q33566110 | ||
| A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss | Q33610901 | ||
| Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas | Q33659249 | ||
| The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans | Q33833964 | ||
| The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases | Q34049252 | ||
| Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio | Q34538249 | ||
| Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses | Q35034902 | ||
| Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss | Q35311994 | ||
| Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response | Q35557923 | ||
| Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways | Q35616707 | ||
| Bone loss in inflammatory arthritis: mechanisms and treatment strategies | Q35808004 | ||
| Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | Q35877149 | ||
| Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin | Q35913720 | ||
| Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features | Q36245883 | ||
| IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. | Q36806362 | ||
| The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond | Q36897200 | ||
| Review: Immune cells and mediators of inflammatory arthritis | Q37118782 | ||
| IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. | Q37497970 | ||
| Cellular sources of IL-17 in psoriasis: a paradigm shift? | Q38231403 | ||
| Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). | Q38438153 | ||
| IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model | Q38500014 | ||
| Pathogenesis of ankylosing spondylitis - recent advances and future directions. | Q38690443 | ||
| New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis | Q38799600 | ||
| Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis | Q38855759 | ||
| Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | Q38958215 | ||
| The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. | Q39017714 | ||
| Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study | Q39104006 | ||
| Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease | Q39251627 | ||
| Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro | Q39583710 | ||
| Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts | Q39842848 | ||
| No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA. | Q40063353 | ||
| Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors | Q40727130 | ||
| Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis | Q40740817 | ||
| Quantitative and Qualitative Changes of Bone in Psoriasis and Psoriatic Arthritis Patients | Q41134931 | ||
| IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis | Q41353840 | ||
| Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis | Q41476975 | ||
| Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis | Q41752189 | ||
| Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondylarthritis | Q41859496 | ||
| Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction | Q41927546 | ||
| Functional role of IL-22 in psoriatic arthritis | Q42326323 | ||
| Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis | Q42534690 | ||
| IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways | Q43245536 | ||
| Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. | Q44122281 | ||
| Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis | Q44688981 | ||
| Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. | Q45905113 | ||
| IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. | Q45960055 | ||
| IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells | Q46043893 | ||
| Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis | Q46154278 | ||
| Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis | Q46275403 | ||
| IL-17 inhibits osteoblast differentiation and bone regeneration in rat. | Q46882790 | ||
| Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial | Q46911236 | ||
| Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model | Q48027870 | ||
| The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling | Q48283709 | ||
| Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. | Q50034719 | ||
| The positive effects of secreting cytokines IL-17 and IFN-γ on the early-stage differentiation and negative effects on the calcification of primary osteoblasts in vitro | Q50038120 | ||
| Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints | Q50099588 | ||
| IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. | Q50771304 | ||
| Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. | Q50906224 | ||
| Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. | Q51556848 | ||
| IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. | Q51680495 | ||
| Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. | Q51873041 | ||
| Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. | Q52907675 | ||
| Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. | Q53347901 | ||
| RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. | Q53487298 | ||
| Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography | Q54263199 | ||
| Lights and shadows of NSAIDs in bone healing: the role of prostaglandins in bone metabolism. | Q55337209 | ||
| Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis. | Q55339808 | ||
| Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study | Q56967235 | ||
| Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis | Q57667239 | ||
| Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 | ||
| T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 | ||
| Genetic Variants of the IL-23R Pathway: Association with Psoriatic Arthritis and Psoriasis Vulgaris, but No Specific Risk Factor for Arthritis | Q59498834 | ||
| Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor | Q73490934 | ||
| Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes | Q74602889 | ||
| High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study | Q79422602 | ||
| Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation | Q80809164 | ||
| Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts | Q82240437 | ||
| Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans | Q83155016 | ||
| IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17 | Q84511967 | ||
| Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis | Q84819852 | ||
| Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice | Q85887884 | ||
| Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study | Q90422581 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 631-640 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis | |
| P478 | volume | 14 |
| Q100465143 | Applying precision medicine to unmet clinical needs in psoriatic disease |
| Q100750215 | Association between serum CCL-18 and IL-23 concentrations and disease progression of chronic obstructive pulmonary disease |
| Q92454999 | DEL-1-Regulated Immune Plasticity and Inflammatory Disorders |
| Q97561265 | Dermatologists' Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations |
| Q92211785 | Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study |
| Q91590639 | Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients |
| Q90232133 | Enthesitis in psoriatic arthritis (Part 1): pathophysiology |
| Q92323296 | H19 Increases IL-17A/IL-23 Releases via Regulating VDR by Interacting with miR675-5p/miR22-5p in Ankylosing Spondylitis |
| Q99240843 | New insights into IL-17/IL-23 signaling in ankylosing spondylitis (Review) |
| Q64079860 | Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases |
| Q89820667 | Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System |
| Q92796625 | Prevalence, clinical features and treatment pattern of patients with concurrent diagnoses of rheumatoid arthritis and psoriatic disease: results of a 14-year retrospective study in a tertiary referral center |
| Q90026306 | Pro- and anti-inflammatory eicosanoids in psoriatic arthritis |
| Q91695718 | Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study |
| Q92949036 | Systemic effects of IL-17 in inflammatory arthritis |
| Q90262614 | The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis |
| Q91664106 | The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies |
| Q64075123 | What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss? |
| Q90046667 | [Pathogenesis of spondylarthritis : Relevance for treatment] |
| Q90155672 | [Rheumatism and bone metabolism] |
| Q90479558 | mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo |
Search more.